These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 35190442

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
    Mavrakanas TA, Gariani K, Martin PY.
    Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
    Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, OPAL-HK Investigators.
    N Engl J Med; 2015 Jan 15; 372(3):211-21. PubMed ID: 25415805
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K, Ohtsu H, Uchida S, Kaname S, Arakawa Y, Fujita T, EVALUATE Study Group.
    Lancet Diabetes Endocrinol; 2014 Dec 15; 2(12):944-53. PubMed ID: 25466242
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Patiromer to Reduce Albuminuria Through Increased Renin Angiotensin Aldosterone System Inhibition in Patients With CKD-A Feasibility Trial.
    Mårup FH, Peters CD, Nielsen SF, Nygaard L, Madsen B, Mose FH, Birn H.
    Kidney Int Rep; 2024 Aug 15; 9(8):2399-2409. PubMed ID: 39156169
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
    Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN.
    Br J Clin Pharmacol; 2012 Mar 15; 73(3):447-54. PubMed ID: 21950312
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.